Clinical Trial

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-18; most recent amendment 2026-03-18.
Status change: Not Yet Recruiting → Recruiting 2025-03-31
Trial Details
NCT Number NCT06891560
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Astellas Pharma US, Inc.
Conditions Adenoid Cystic Carcinoma
Enrollment 34 participants
Start Date 2025-03-31
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-06